Product Description
Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects. Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607063.html)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Canada, China, Czech Republic, France, India, Italy, Jordan, Korea, Lebanon, Netherlands, New Zealand, Poland, Saudi Arabia, Spain, Tunisia, United States, Unknown Location
Active Clinical Trial Count: 23
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Chronic Myeloid Leukemia
Phase 2: Acute Myeloid Leukemia|Breast Cancer|Chronic Lymphoid Leukemia|HIV Infections|Inflammation|Leukemia|Lymphoma, Non-Hodgkin|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Nose Cancer|Oncology Unspecified|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|T-Cell Leukemia|T-Cell Peripheral Lymphoma
Phase 1: B-Cell Leukemia|Blast Crisis|Healthy Volunteers|Leukemia, Plasma Cell|Lymphoid Leukemia|Lymphoma, B-Cell|Mesothelioma|Multiple Myeloma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HEM-iSMART B | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2031-10-01 |
|
| CA180-226 | P2 |
Unknown Status |
Chronic Myeloid Leukemia |
2030-04-25 |
|
| SJALL23T | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|T-Cell Peripheral Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2027-12-01 |
|
| NCI-2021-08486 | P2 |
Recruiting |
Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia |
2026-10-30 |